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Summary Prostatic adenocarcinoma commonly metastasizes to bone. Unlike most other bony secondaries, the majority of skeletal prostatic
metastases are osteoblastic rather than osteolytic i nature. Several growth factors which are known to stimulate bone formation are
expressed in benign and malignant prostate cells. bi none has been specifically linked to osteoscierotic metastases. Bone morphogenetic
proteins (BMPs) induce ectopic bone formation in vivo. We have reported previously that BMP-6 mRNA and protein are expressed in the
majority of primary prostatic carcinomas with established skeletal metastases but rarely in clinically organ-confined tumours. This study
examines the expression of BMP-6 mRNA in matched prostatic primary and secondary bony lesions and in isolated skeletal metastases from
prostatic adenocarcinomas, as well as other common human malignancies, by in situ hybridization. BMP-6 mRNA was detected in 11 out of
13 bone metastases from prostate carcinoma and in three paired samples of primary prostate carcinoma and matching skeletal metastasis.
Weak signals for BMP-6 were also present in 5 out of 17 skeletal deposits from non-prostatic malignancies. BMP-6 mRNA appears to be
strongly expressed in prostatic adenocarcinomas, both in the primary tumour and in bone metastases. It is also expressed, though less
frequentty, in skeletal metastases from other human carcinomas. Our findings suggest that BMP-6 may hold potential as an attractive marker
and possible mediator of skeletal metastases, particularly in prostate carcinoma.
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Metastases are the most common neoplastic lesions in bone. and
more than 80%-7 of the tumours are accounted for by a limited
number of primary malignancies (Orr et al. 1995). These include
carcinomas ofthe breast, prostate. thyroid. kidney and lungy. Normal
bone is being remodelled continuously with new bone formation by
osteoblasts and bone degradation by osteoclasts. In the presence of
skeletal metastases. there is a disturbance of the fine balance
between the two processes. When bone destruction dominates there
is net loss of bone mass and the lesion is described as osteolytic.
W'hen excessise amounts of new bone formation takes place with
less bone destruction. the lesion is described as osteoblastic or
osteosclerotic. This type of increased ossification only occurs in
relatively acellular skeletal metastases associated with the deselop-
ment of a fibrous stroma. and is particularly common in metastases
from prostatic carcinoma (Galasko. 1982). Human prostatic adeno-
carcinoma is one of the rare cancers that consistently produces
osteoblastic metastases to bone. in approximately 90% of cases.
Several growth factors which are known to stimulate osteoblast
growth and bone matrix formation are also expressed in benign and
malignant prostate cells. These include members of the fibroblast
growth factor. insulin-lke growth factor. platelet-denried growth
factor and transforming growth factor-beta (TGF-0) families
(Bavlink et al. 1993: Ware. 1993). Bone morphogenetic protein
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(BMP) refers to an actisvitv originallx densfed from bone that is able
to induce ectopic bone formation in ViVO (Unst. 1965). To date.
more than 15 BMPs have been identified (Dube and Celeste. 1996)
andthey are all. except BMP-1. members ofthe TGF-, superfamily
of peptide growth factors. Prostate cancer is the second most
common male malignancN in Europe. with over 85 000 cases re-is-
tered every year (Jensen et al. 1990). In the United States of
America it is the most common malianancx in men. with an esti-
mated 209 900 nesw cases diagnosed in 1997 (Wingo et al. 1997).
Skeletal metastases represent the most common cause of morbiditv
in men with advanced disease. and there is no clear explanation for
their osteoblastic nature.
Pilot work. using the reverse transcriptase pol%-merase chain
reaction (RT-PCR) to detect mRNA for BMPs 1-6. showed differ-
ential expression in benign and malignant prostatic tissue. w-ith
BMP-6 being expressed in over 50% of primars tumours swith
established bony secondaries (Bentley et al. 1992). We hasve
shown recentlv that BMP-6 mRNA and protein are exclusisels
expressed in epithelial cells in the prostate and BMP-6 is found
more commonly in primary tumours Awith established metastatic
secondaries (Hamdv et al. 1997). Other studies have in'estigated
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Table 1 BMP-6 expression in skeletal metastases from different primary
carcinomas
Skeletal metastases from different Number of klsions
primary carcnomas (n) expressing BMP-6
Prostate 13 11
Breast 5 3
Lung 8 1
Coon 1 1
Kidney 2 0
Uterus 1 0
BMP expression in human and rat prostate and in prostate carci-
noma cell lines by Northem blot analysis. RT-PCR and immuno-
histochemistry. demonstrating various patterns ofgene and protein
expression (Harris et al. 1994a: Barnes et al. 1995). However. the
expression of BMPs in metastatic lesions has not been studied
previously. The aim ofthe present study was to investigate BMP-6
gene expression in matched prostatic primary and secondary
lesions and in isolated skeletal metastases from prostatic adenocar-
cinomas. as well as other common human malignancies by in situ
hybridization. The results and their implications are discussed.
MATERIALS AND METHODS
Tissue
Archival tissue was obtained from 30 patients with established
skeletal metastases from different primary cancers. The metastatic
lesions were fromprimary carcinomas ofprostate (n = 13). lung In =
8). kidney (n = 2). breast (n = 5). colon (n = 1) and uterus (n = 1). In
addition. primary prostatic malignant tissue from 3 ofthe 13 patients
with skeletal secondaries was obtained from transurethral resection
specimens. The tissue was fixed in 10%A neutral buffered formalin
and specimens containing calcified matenral were decalcified in
Gooding and Stewart's decalcification fluid. All tissue samples were
processed and embedded in paraffin wax. Sections were cut at 3 gm.
mounted on 3-aminopropyltriethoxysilane (APES)-coated slides
and dried overnight at 37C followed by 1 h at 56CC.
BMP-6 nboprobes
A 758-bp fragment ofthe human BMP-6 cDNA. representing bases
1019-1776 ofthe published sequence. was amplified by PCR using
placental cDNA as the template with the following oligo-
nucleotides: 5'-TCCTGACCTGTrl-lGTFG-3' and 5'-CT C-
CGTGl IT1T-lTAAGGC-3'. The fragment was cloned in forward
and reverse orientation into the pBluescript SK+ vector (Stratagene.
UK). DNA sequencing analysis was performed on this fragment and
showed it to be identical to the published BMP-6 cDNA sequence
(GenBank accession number M38694) (Celeste et al. 1990).
Recombinant plasmids were linearized with SmaI and gel purified
from low melting point agarose using standard conditions. The puri-
fied DNA was subsequently phenol extracted under RNAase-free
conditions. ethanol precipitated and resuspended in diethyl-pyrocar-
bonate-treated water. Sense and antisense riboprobes were synthe-
sized by in vitro transcnption using7 T7 RNA polymerase and
the Dig-RNA labelling kit (Boehringer Mannheim. UK). Each
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Figure 1 Photomicrograph of in situ hybridization for BMP-6 on a section of (A) prostatic skeletal metastasis, and (B) matching prinmary prostatic carcinoma
(magnification = approximately x 400)
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transcription reaction contained 1 jg of cDNA and the yield of
digoxigenin-labelled RNA was estimated by spot-blot analysis.
In situ hybridization
In situ hybridization was performed as previously described
(Hamdy et al, 1997). The sections were pretreated with 30 jig ml-l
proteinase K for 30 min at 370C, and acetylated in 0.25% acetic
anhydride in 0.1 M triethanolamine. Prehybridization buffer (50%
fornamide, 4 x SSC. 1 x Denhardt's solution, 125 jg ml tRNA
and 100 jig ml-' freshly denatured salmon sperm DNA) was
applied to the sections for 30 min at 55°C, drained and replaced
with hybridization solution (prehybridization buffer containing
500 ng probe ml-l). The sections were hybridized overnight at
55°C. After hybridization, the sections were washed to a final
stringency of0.1 x SSC/50% fonnamide at 550C. The hybridized
probe was detected with an anti-digoxigenin antibody labelled
with alkaline phosphatase (Boehringer Mannheim) diluted 1:500,
and the reaction was visualized with a colour substrate solution
(nitro-blue-tetrazoliuml5-bromo-4-chloro-3-indolyl-phosphate in
0.1 M Tris. 0.1 M sodium chloride, 0.05 M magnesium chloride pH
9.5). To block endogenous alkaline phosphatase activity in skeletal
tissues, 1 mM levamisole was added to the colour substrate solu-
tion immediately before use. The colour reaction was allowed to
develop ovemight in the dark. The sections were counterstained
with haematoxylin and mounted with Glycergel (Dako, UK).
Statistical analysis
Fisher's exact test was used for statistical analysis. P-values less
than 0.05 were considered significant.
RESULTS
Thirty bone metastases. three ofwhich had corresponding primary
prostate carcinoma tissue, were studied with the BMP-6 antisense
and sense probes. Messenger RNA for BMP-6 was identified in
normal osteoblasts in skeletal tissue. This was used as an internal
positive control andindicatorofmRNA integrity in all the samples
investigated.
In bone metastases from prostatic adenocarcinomas, positive
signals for BMP-6 were observed in 11 out of 13 lesions (85%)
compared with 5 out of 17 (29%) skeletal deposits from non-
prostatic malignancies (P = 0.0039). These included primary
breast (3 out of 5, one of which had mixed osteolytic and
osteoblastic changes), lung (1 out of 8) and colon (1 out of 1)
carcinomas (Table 1). No expression of BMP-6 was found in
skeletal metastases from primary renal or uterine carcinomas. The
hybridization signals, which appeared as purple/black cytoplasmic
staining, were intense and homogeneous. In the three paired
samples of primary and secondary prostate carcinoma, both
lesions expressed BMP-6 and the expression was exclusive to
malignant epithelial cells (Figure 1). While the majority of these
cells in the metastatic lesions showed strong expression ofBMP-6,
varying degrees of expression were observed in the primary
tumours. The signals for BMP-6 observed in secondaries from
non-prostatic carcinomas appeared weaker than in primary and
secondary prostate carcinoma cells. When hybridization was
performed with the BMP-6 sense probe on serial sections, no
signals were observed.
DISCUSSION
Since the discovery of BMPs in 1965, research has focused on
identification and purification of these proteins (Bauer and Urist,
1981: Urist et al, 1982, 1984). and, more recently. on under-
standing the role of BMPs in normal human embryonic develop-
ment. The proteins have a variety of functions in embryogenesis
including normal limb, skin, tooth and heart development (Lyons
et al, 1989, 1990). Their osteoinductive ability in vivo has also
stimulated the development ofpotential therapeutic applications in
reconstructive orthopaedic, periodontal and craniofacial surgery
(Wang et al, 1990; Stone, 1997). BMPs are actively involved in
bone formation and have the capacity to induce differentiation of
mesenchymal cells into cartilage and then into bone. These effects
have been observed both in vivo and in vitro (Urist et al, 1983).
Osteoblasts express BMP as they differentiate to forn mineralized
bone (Harris et al, 1994b), and it has been suggested that BMPs
may be involved in directing cells along the osteoblast lineage
(Mundy, 1996). BMPs have also been described in malignant bone
tumours, in particular human osteosarcomas (Jin and Yang. 1990:
Yang and Jin, 1990; Yoshikawa et al. 1994a, 1994b). In non-
skeletal cancers, very few efforts have been made to link BMP
activity with the development and progression of cancer. This is
not surprising in view ofthe behaviour of most skeletal metastases
with increased bone resorption and osteoclastic activity, a process
which is not generally associated with BMP activity. However.
prostatic adenocarcinoma commonly gives rise to osteosclerotic
bone lesions with apredilection for the axial skeleton (Saitoh et al.
1984). Previous work has demonstrated a potential association
between BMP expression, in particular BMP-6, and the presence
of skeletal metastases in prostate carcinoma (Bentley et al. 1992;
Harris et al, 1994a; Barnes et al, 1995).
More recently, we have shown that the majority of primary
prostatic tumours with established skeletal metastases express
BMP-6 both at protein and mRNA levels, while most clinically
organ-confined prostatic carcinomas are negative for BMP-6
(Hamdy et al, 1997).
In this study, we have used in situ hybridization to examine the
expression ofBMP-6 in matched primary and secondary prostatic
adenocarcinomas and in isolated skeletal metastases from prostate
carcinomas and other common human malignancies. We found
that BMP-6 mRNA is strongly expressed in the majority of
skeletal metastases from prostatic adenocarcinomas. Despite our
limited number ofcorresponding primary prostatic tumours. when
the three matched samples were examined they were also found to
express BMP-6 and the expression was exclusive to the malignant
epithelial cells, a finding we have reported recently (Hamdy et al,
1997). It was interesting to observe that, although present in a
minority of skeletal secondaries from other human malignancies.
BMP-6 signals in these cases were considerably weaker than in
prostatic secondaries.
BMP-6 has been shown previously to be expressed in both
normal and malignant prostatic tissue (Harris et al, 1994a) with
slightly elevated levels of mRNA expression in the malignant
tissue (Bames et al, 1995). One study by Bentley et al (1992)
showed, by RT-PCR, that BMP-6 was selectively expressed in
primary prostatic tumours ofpatients with positive bone scans and
absent in non-metastatic tumours, benign tissue and ocular
melanoma, which rarely metastasizes to bone, in accordance with
our recent findings.
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Several studies have suggested that BMPs are involved in the
complex process of osteoblast differentiation, but the functional
differences between individual BMPs are not well understood. In a
bone nodule-forming assay utilizing rat osteoprogenitor cells,
BMP-6 was shown to produce larger nodules than BMP-2 and
BMP-4 and possibly to act on an earlier stage progenitor cell
(Hughes et al, 1995). Similar findings were reported by Boden et
al (1996), who estimated BMP-6 to be a 2- to 2.5-fold more potent
inducer of osteoblastic differentiation than BMP-2 and BMP-4.
Osteoblastic extracellular matrix was also shown to increase
mRNA levels of BMP-6, but not BMP-2 and BMP-4, in the
uncommitted mesenchymal ROB-C26 cells (Shi et al, 1995). In
contrast, BMP-2 and BMP-4 are more potent in inducing an
osteoblastic phenotype in bone marrow stromal cells than BMP-6
(Yamaguchi et al, 1996), and BMP-2 has greater chemotactic
effect on in vitro migration ofhuman osteoblasts than BMP-4 and
BMP-6 (Lind et al, 1996). The role of the murine homologue of
BMP-6, Vgr-l, in endochondral bone formation was investigated
in an elegant study by Gitelman et al (1994). Chinese hamster
ovary (CHO) cells transfected with Vgr-l, when injected subcuta-
neously into nude mice, were shown to produce tumours with
well-developed vasculature and areas ofbone and cartilage forma-
tion. In comparison, the tumours formed by the parental cells
became necrotic and haemorrhagic and, more importantly, lacked
the cartilage and bone formation completely.
Benign and malignant prostate cells produce a numberofgrowth
factors with mitogenic activity for osteoblasts (Baylink et al, 1993;
Ware, 1993), but none of these factors has been specifically linked
to the inreased osteoblastic activity seen in skeletal lesions
secondarytoprostate cancer. However, some studies have suggested
the presence of a mitogen produced by metastatic prostate cancer
cells, which stimulates osteoblastic proliferation with high speci-
ficity (Koutsilieris et al, 1987a, 1987b; Perkel et al, 1990).
There is growing evidence that BMP-6 gene expression is asso-
ciated with primary prostate carcinomas that have metastasized to
bone and their skeletal secondaries.
Although the aim ofthe current study was not to investigate the
role of BMP-6, one could speculate that this potent protein may
facilitate the development of skeletal metastases in prostate carci-
noma, and may be responsible fortheirosteoblastic nature. Further
studies are warranted to investigate the potential function of
BMPs, and BMP-6 in particular, in the progression of early
prostate carcinoma to the metastatic phenotype.
ACKNOWLEDGEMENTS
This study was supported by the Freeman Hospital Trustees,
Newcastle upon Tyne, UK, and a Biomed H grant from the
European Commission, grant number PL95-0453.
REFERENCES
Bares J. Antiony CT. Wall N and Steiner MS (1995) Bone morphogenetic protein-
6 expression in normal and malignant prostate. WorldJ Urol 13: 337-343
Bauer FCH and Urist MR (1981) Human osteosarconm-derived soluble bone
morphogenetic protein. Cln Orthop 154: 291-295
Baylink DJ. Finkelman RD and Mohan S (1993) Growth factors to stimulate bone
formaion. JBone MinerRes 8: S565-S572
Bentley HL y FC. Har KA. Seid JM. williams -L Johnstone D and Russell
RGG (1I992) Expression ofbone morphogenetic prtins in human prostic
ndcxardinom and benign prOStic hypepasia BrJCancer*6: 1159-1163
Boden SD. McCuag K Hair G. R;cine M. Tiu L Wozney JM and Nanes MS
(1996) Differential effects and glucocorficoid potentiation ofbone
moxphogeneuc protei action during rat osteoblast differentiation in Vitro.
Endocrinology 137: 3401-3407
Celeste AJ. lannazi JA, TaylorRC, Hewick RM. Rosen V. Wang EA and Wozney
JM (1990) Identifiation oftranforming growth-factor-beta family members
present in bone-inductive proten purified from bovine bone. Proc NailAcad
Sci USA 87: 9843-9847
Dube JL and Celeste AJ (1996) Human bone morphogenetic protein-15. a new
member ofthe transforming growth-factor-beta superfanily. J Bone MinerRes
11: T330-T330
Galasko CSB (1982) Mechanisms oflytic and blastic metastatic disease ofbone.
Clin Orthop 169 20-27
Gitelman SE. Kobrin MS. Ye JQ. Lopez AR. Lee A and Deyck R (1994)
Recombinant Vgr-I/BMP-6 expressing tmors induce fibrosis and
endehondral bone formantion in vivo. J Cell Biol 12: 1595-1609
Hamdy FC. Autzen P. Robinson MC, Horne CHW. Neal DE and Robson CN (1997)
Immunolocalizati and messenger RNAexpression ofbone morphogenetic
protein-6 in human benign and malignant prostatic tissue. CancerRes 57:
4427-4431
Harris SE. HarTis MA. Mahy P. Wozney J. Feng JQ and Mundy GR (1994a)
Expression ofbone morphogenetic protein messenger RNAs by normal rat and
human prostate and prostate cancer cells. Prostate 24: 204-211
Harris SE. Sabatini M. Harris MA. Feng J. Wozney J and Mundy GR (1994b)
Expression ofbone morphogenetic protein messenger RNA in prolonged
cultures offetal rat calvarial cells. JBone MinerRes 9: 389-394
Hughes FJ, CollyerJ. Stanfield M and Goodman SA (1995) The effects ofbone
morphogenetic protein-2. 4, and -6 on differentiation ofrat osteoblast cels in
vitro. Endocrinology 136: 2671-2677
Jensen OM. Esteve J. Moler H and Renard H (1990) Cancer in the European
community and its member states. EurJ Cancer26: 1167-1256
Jin Y and Yang U (1990) Immunohistochemical analysis ofbone morphogenetic
protein (BMP) in osteosarna. JOral Pathol Med 19: 152-154
Koutsilieris M. Rabbani SR and Goltzman D (1987a) Effects ofprostatic mitogens
on rat bone ceUs and fibroblasts. JEndocrinol 115: 447-453
Koutsilieris N. Rabbani SA. Bennett HP and Gohzman D (1987b)Clhracteristics of
prosate-derived growth factors forcells ofthe osteoblast phenotype. JClin
Invest 86: 941-946
Lind N. Eriksen EF and Bunger C (1996) Bone morphogenetic protein-2 but not
bone morphogenet protein-4 and -6 stimulates chemotactic migration of
human osteoblasts. human marrow osteoblasts. and U2-OS cells. Bone 18:
53-57
Lyons KM. Pelton RW and Hogan BLM (1989) Pattems ofexpression of murine
Vgr-I and BMP-2a RNA suggest that transforming growth factor-beta-like
genes coordinatly regulate aspects ofembryonic development. Genes Dev 3:
1657-1668
Lyons KM. Pelton RW and Hogan BLM (1990) Organogenesis andpaen
fonratio in the mouse: RNA distribution pattrns suggest a role for bone
morphogenetic protein-2a (BMP-2a). Development 16:833-844
Mundy GR (1996) Regulaion ofbone formation by bone morphogenetic proteins
andothergrowth factors. Clin Orrhop 323: 24-28
Orr FW. Sanchez-Sweatman OH. Kostenuik P and Singh G (1995) Tumor-bone
interactions in skeletal metastasis. Clin Orthop 312: 19-33
Perkel VS. Mohan S. Herring SJ. Baylink DJ and linkhart TA (1990) Human
prostatic cancer cells. PC3. elaborate mitogenic activity which selectively
stimulates human bone cells. CancerRes 50: 6902-6907
Saitob H. Hida M. ShimboT. Nakamura K. Yamagata J and Satoh T (1984)
Metastatic patterns ofprostatic cancer - cofrelaion between sites and number
oforgans involved. Cancer54: 3078-3084
Shi S. KirkIM and Kahn A (1995) Osteoblastic exracellular matrix modulates up-
regulated genes expression ofTgf-Beta-2. Vgr-l/BMP-6 and osteoblast
phenotype markers ofmultipotential mesenchymal cells(absract). JBone
Miner Res 16: S340-S340
Stone CA (1997) A mokcular approach to bone regeneration. BrJPlast Surg 50:
369-373
Urist MR (1965) Bone formation by autoinduction. Science 150: 893-899
Urist MR. Liete A. Mizutani H. Takagi K. Triffitt J. Amstutz J. Delange R. Termine
J and Funeran GAM (1982) Abovine low-molecular weight bone
morphogenetic protein (BMP) fraction. Chin Orthop 162: 219-232
Urist MR. DeLange RJ and Fmerman GAM (1983) Bonecel differentiation and
growth factors. Scece 220- 680-686
Un'st MR. Huo YK. Brownell AG. Hohl WM. Buyske J. Lietze A. Tempst P.
Hunkapiller M and DeLange RJ (1984) Purification ofbovine bone
mophogeneic protein by hydroxyapatite chromatography. Proc NailAcad Sci
LUSA 81: 371-375
Brfiish JournalofCancer (1998) 78(9J, 1219-1223 0 CancerResearch Campaign 1998BMP-6 expression in skeJetalmersases 1223
Wang EA. Rosen V. Dalessandro JS. Bauduy M. Cordes P. Harada T. Israel DL
Hewick RM. Kerns KM. Lapan P. Luxenberg DP. McQuaid D. Moutsatsos IK.
Nove J and Wozney JM 1990) Recombinant human bone morphogenetic
protein induces bone-fornanocL Proc NatiAcadSci USA 87: 2220-2224
Ware JL (1993) Growth factors and their recetors as determinants in the
proiferation and metastasis ofhuman prostate cancer. CancerMetastasis Rev
12: 287-301
Wmgo PA. Landis S and Ries LA (1997) An to the 1997 estimate for
new prostate cancer cases. CA CancerJClin 47: 239-242
Yamaguchi A. Ishizuya T. Kintou N. Wada Y. Katagiri T. Wozney JM. Rosen V and
Yoshiki S (1996) Effects ofBMP-2. BMP-4. and BMP-6 on osteoblastic
differentiation ofbone marrow-derived stromal cell-lines. ST2 and MC3T3-
G2/PA6. Biochem Biophvs Res Commun 22& 366-371
Yang Li and Jin Y (199O) Immwhistochemical obserations on bone
morphogenetic protein in normal and abnormal conditions- Clin Orthop 257:
249-256
Yoshikawa H. Rettig WJ. Lane JM. Takoa K Akldrman E. Rup B. Rosen V.
Healey JI. Huvos AG and GarinChesa P (1994a) Immunohistochemical
detection ofbone mrophogenetic proteis in bone and soft-iissue sarcomas.
Cancer74: 842-847
Yoshikawa H. Rettig WJ. Takaoka K. Aldeman E. Rup B. Rosen V. Wozney JM.
Lane JM. Huvos AG and GarinChesa P 1994b) Expression ofbone
morphogenetic proteins in human osteosarcoma: immunohistochemical
detection with monoclonal antibody. Cancer 73: 85-91
C Cancer Research Campaign 1998 Britsh Journal ofCancer(1998) 78(9), 1219-1223